MIT engineers are hoping to help doctors tailor treatments to patients' specific heart form and function, with a custom robotic heart. The team has developed a procedure to 3D print a soft and flexible replica of a patient's heart. No two hearts beat alike. The size and shape of the the heart can vary from one person to the next. These differences can be particularly pronounced for people living with heart disease, as their hearts and major vessels work harder to overcome any compromised function.

The Position In Roche s Pharmaceutical Research and Early Development organisation (pRED), we make transformative medicines for patients in order to tackle some of the world's toughest unmet healthcare needs. At pRED, we are united by our mission to transform science into medicines. Together, we create a culture defined by curiosity, responsibility and humility, where our talented people are empowered and inspired to bring forward extraordinary life-changing innovation at speed. This position is located in Computer-Aided Drug Design (CADD), a department within Small Molecule research, where the computer-aided discovery of chemical starting points and further optimization towards clinical candidates is the primary focus. To ensure excellence in drug design, we push the scientific boundaries in key areas of CADD, implement and democratize new computational tools, and advocate a digital mindset across the organization.

Today Roche announced a new collaboration with Bristol Myers Squibb that will use cutting edge digital methods to improve standardization and interpretation of tissue-based assays and will leverage Roche's established partnership with PathAI. Roche plans to integrate a novel PathAI-developed algorithm for biomarker analysis into their digital pathology workflow software. The AI-powered algorithm will be used to analyze clinical trial samples and generate biomarker data. These imaging tools will enable very precise diagnoses that will lead to personalized treatment options for patients with solid tumors. In October 2021, Roche announced a strategic partnership with PathAI.

Today Roche announced a new collaboration with Bristol Myers Squibb that will use cutting edge digital methods to bring significant improvements in standardization and interpretation of tissue-based assays. This new partnership will leverage Roche's established partnership with PathAI. Through this new collaboration, Roche will integrate a novel PathAI-developed algorithm for biomarker analysis into their digital pathology workflow software. The AI-powered algorithm will be used by Bristol Myers Squibb to analyze clinical trial samples and generate biomarker data. These pathology imaging tools will enable very precise diagnoses that will lead to personalized treatment options for patients with solid tumors.

"Our commitment is to provide the best possible care for our patients, and it is increasingly clear that AI-powered pathology can radically enhance diagnostic accuracy and treatment selection." PathAI and Cleveland Clinic have announced a 5 year strategic collaboration. The partnership will combine PathAI's AI-based platforms with Cleveland Clinic's clinical expertise and multi-modal data to unlock a broad implementation of next-generation pathology diagnostics. The objective is to accelerate innovation in precision pathology and to bridge communities in the healthcare ecosystem including patients, biopharma, and academic research. Cleveland Clinic will leverage PathAI's quantitative pathology algorithms to conduct new translational research and for use as clinical diagnostics in multiple disease areas.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the research use only (RUO) launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for breast cancer, which are important biomarkers for breast cancer patients. Breast cancer is the second most common cancer in the world with an estimated 2.3 million new cases in 2020¹ and is the most common cancer in women globally¹,². These new algorithms complete the Roche digital pathology breast panel of image analysis algorithms. This includes a whole slide analysis workflow with automated pre-computing of the slide image prior to pathologist assessment, and a clear visual overlay highlighting tumour cells with and without nuclear staining. Intended for use with Roche's high medical value assays and slides stained on a BenchMark ULTRA instrument using ultraView DAB detection kit, the uPath Ki-67 (30-9) image analysis, uPath ER (SP1) image analysis and uPath PR (1E2) image analysis algorithms are ready-to-use and integrated within Roche's uPath enterprise software and NAVIFY Digital Pathology, the cloud version of uPath.

The Institute of Information Technology Professionals South Africa (IITPSA) has welcomed the plans by the South African Revenue Service to use big data analytics and artificial intelligence to improve revenue collection and locate tax evaders. IITPSA Board member Moira de Roche says the move is welcome, if overdue. "It should have been done years ago. The more efficiently SARS collects tax that is due, the better off we will be as a country. It has been relatively easy for people to dodge tax before now, so it is a move in the right direction to start using all the data that exists across various government departments and deploying AI to identify trends and potential fraud."

The duration of RPF project is initially set for two years, with the possibility of extension for a third year. You will be based in Basel, Switzerland with possible stays at the academic partners. The start date of this fellowship is within 2020 or on availability. Please clearly indicate your preferred starting date on your motivation letter. All applications need to include a CV, motivation letter, a publication list and, if available, your PhD.

For life science companies, healthcare providers, patients, and consumers, AI offers great potential to streamline processes and achieve better treatment results. Dr. Anna Bauer-Mehren describes the role of real-world data, data science or data analysis in pharmaceutical research and the resulting new opportunities for personalized medicine. In particular, she addresses the importance of high-quality data and Roche's efforts to make data FAIR. In their view, this is essential for the success of AI methods in R&D. Using several examples, she shows in which areas of pharmaceutical research AI is already being used successfully, but also discusses which areas still have great challenges.

The march toward personalization means marketing strategy finds itself under the expanding shadow of artificial intelligence. AI is being deployed in a growing number of functions. I recently asked Jerry Roche, CEO of Trial Run, a fractal analytics firm, for his perspective on the impact of AI on marketing strategy. Paul Talbot: Are AI capabilities changing the way we create and manage marketing strategy? Jerry Roche: Given the need to serve personalized experiences to a large customer base, marketers can no longer rely on intuitive heuristics targeted to the lowest common denominator.